Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing prior clinical trials and regulatory decisions
PubMed 37558377 · doi:10.1016/j.jacc.2023.05.055
What was done
This narrative review summarizes clinical trial evidence, pharmacology, and regulatory status regarding low-dose oral colchicine (0.5 mg/day) as an anti-inflammatory strategy for secondary prevention in coronary artery disease patients receiving guideline-directed medical therapy.
What was found
The authors report that low-dose colchicine lowers major adverse cardiovascular events by 31% in stable atherosclerosis and by 23% after recent myocardial infarction. The abstract notes that colchicine is contraindicated in significant renal or liver dysfunction and requires temporary discontinuation when co-administered with clarithromycin, ketoconazole, or cyclosporine. The U.S. FDA approved low-dose colchicine in June 2023 for cardiovascular event reduction in adult atherosclerotic disease.
Why it matters
It highlights the clinical and regulatory transition of targeted anti-inflammatory therapy into standard secondary prevention alongside lipid lowering.
Limits
As a narrative review, it lacks systematic search criteria and quantitative synthesis. Specific sample sizes, confidence intervals, absolute event rates, and safety data from individual trials are not detailed in the abstract.
Cited by
- supports Colchicine is an anti-inflammatory drug identified through Harvard research by Paul Ridker to reduce cardiovascular risk.